Objective: To determine whether probiotics supplementation affects intestinal blood flow velocity in extremely low birth weight neonates.
Introduction
Probiotics are defined as an oral supplement or a food product that contains a sufficient number of viable microorganisms to alter the microflora of the host with the potential for beneficial health effects. [1] [2] [3] They are currently being used both for prevention and treatment of intestinal and extraintestinal diseases. 4 In a particularly vulnerable population of preterm neonates, probiotics may promote feeding tolerance and help to prevent necrotizing enterocolitis. 5, 6 Multiple mechanisms of action of probiotics have been proposed including maintenance of the mucosal barrier integrity, regulation of bacterial colonization, modulation of the intestinal inflammation and activation of general intestinal immune defenses. 5 Recently, it has been reported that probiotics are a source of the trace amines, tyramine and b-phenylethylamine, which affect vasculature independently via recently described trace amineassociated receptors. 7, 8 In animal models, amines exert differential effects on aorta/coronary arteries and mesenteric vasculature, causing relaxation of mesenteric vasculature and subsequent improvement in the intestinal blood flow. It has been well established that alterations in intestinal blood flow have an impact on tolerance to enteral feedings in preterm neonates. 9, 10 Our objective was to investigate the effect of probiotics on intestinal blood flow by measuring pre-and postprandial superior mesenteric artery (SMA) blood flow velocity (BFV) in a randomized, placebo-controlled, double-blinded study. We hypothesized that supplementing extremely low birth weight neonates with the probiotics bifidobacteria and lactobacilli would increase their SMA BFV.
Methods
This study was approved by the Saint Louis University Institutional Review Board. Informed consent was obtained from the parents of all enrolled infants. 11 SMA BFV responses to enteral feedings, supplemented either with probiotics or placebo, were recorded once in preterm neonates during the second week of life, after at least 7 days of such supplementation. Pre-and postprandial SMA BFV was measured (0, 30 and 60 min after feeding) and patent ductus arteriosus status was recoreded just prior to preprandial SMA BFV measurement. Preprandial measurements were made at least 3 h after the last feeding. All infants at the time of study were fed with maternal or donor breastmilk.
Study design

Subjects
Infants admitted to the neonatal intensive care unit at the Cardinal Glennon Children's Medical Center were eligible for enrollment. Inclusion criteria were birth weight 501 to 1000 gm, birth weight appropriate for gestational age and chronological age p14 days of age at the time feeding initiation. Eligible infants were randomly assigned to either the probiotic-supplemented or control group. Exclusion criteria were clinical evidence of major congenital anomalies, diagnosis of anemia (venous hemoglobin <10 g dl À1 ) or polycythemia (venous hemoglobin >22 g dl À1 ) and known probiotics supplementation prior to the study entry. Infants receiving vasoactive medications other than caffeine were also excluded.
Enteral feedings
The probiotic group received a supplement consisting of 500 million colony-forming units, each of Lactobacillus rhamnosus GG (Culturelle, Amerifit Brands, Cromwell, CT, USA) and Bifidobacterium infantis (Align, Procter and Gamble, Cincinnati, OH, USA) suspended in 0.5 ml of the mother's milk. Probiotics supplementation was added to the first enteral feeding and continued once daily with feedings thereafter until discharge or until 34 weeks postmenstrual age. Infants randomized to the control group received unsupplemented milk added to their daily feeding. The probiotic supplement was prepared daily by the pharmacy. A specimen from each batch of probiotic product was cultured prior to its use in the study to confirm the organism specie and ensure absence of contamination. Enteral feeding was initiated when deemed appropriate by the attending neonatologist. The feeding schedule guidelines were implemented, with the goal of administering trophic feedings of 10 ml kg À1 day À1 in the first 2 to 3 days. If tolerated, the amount of feeding given was advanced with an increase of not >20 ml kg À1 day À1 . Caloric density of the feeding milk was changed by the addition of fortifier to 24 kcal oz À1 when the feeding volume reached 80 ml kg À1 day À1 . The target for full feeding volume intake was 150 ml kg À1 day À1 . Feeding was stopped if there were signs of feeding intolerance (bilious emesis, abdominal distension or bloody stools) or systemic signs (shock and hypotension). Total parenteral nutrition was given to all the study infants until oral nutrition was tolerated at a volume of 100 to 120 ml kg À1 day
À1
.
Doppler ultrasound studies SMA BFV was measured using pulsed Doppler ultrasound (GE Healthcare, Waukesha, WI, USA) and a 10.0-MHz transducer. The sampling volume of the pulsed Doppler was placed 3 mm distal to the origin of the SMA using a real-time two-dimensional image from a longitudinal abdominal approach, with an angle of insonation <15 degrees. When five stable consecutive waveforms were obtained, the curve was traced and the time-averaged mean velocity (TAMV), peak systolic velocity (PSV) and end diastolic velocity (EDV) were recorded. Evidence of a patent ductus arteriosus was noted prior to the SMA BFV measurements. All ultrasound measurements were performed by one of the two ultrasound technicians, who were not aware of the study subject group allocation.
Statistical analyses
Subject characteristics, feedings, clinical measures and concurrent treatments or possible confounders were described by group: probiotic vs control. Statistically significant differences (a ¼ 0.05) were assessed with a t-test or Chi-square, depending on the continuous or categorical nature of the item. The percent change between baseline and 60-min post was calculated for three BFV measurements (TAMV, PSV and EDV). The nonparametric Wilcoxon rank-sum test assessed differences (a ¼ 0.05) in percent change between probiotic and control subjects for the three BFV measurements. Mean values for the three BFV measurements taken at three time points (that is, baseline, 30-min post and 60-min post) were reported. A power analysis was performed to assess sample-size sufficiency for the expected differences between probiotic and control groups in percent change on three BFV measurements. A sample of 31 subjects (15 probiotics and 16 control) achieves a 92.3% power to detect a relative mean percent change of times times greater in the probiotic vs control group. This power analysis assumes an a ¼ 0.017, a conservative selection to adjust for the multiple comparisons associated with the three outcome measurements.
Results
In all, 31 patients completed the study 15 in the probiotic group and 16 in the placebo group. Out of the 55 subjects, enrolled at SLU as a part of the above mentioned multicenter trial, 9 subjects missed the enrollment because of the substudy Institutional Review Board-approval delay, 5 were not enrolled because of consent refusal, 3 were not fed during the study time and 7 were fed continuously. Three infants died after the study completion but prior to hospital discharge; all were randomized to the placebo group, one had intestinal perforation. Another infant in the placebo group had necrotizing enterocolitis with documented pneumatosis intestinalis and survived. Three infants in probiotic group and six in placebo group had late onset of sepsis; coagulase-negative staphylococcal infections were most common (six cases), whereas two Escherichia coli and one Enterobacter cloacae were recovered.
The demographic and clinical variables of the infants are summarized in Table 1 . Birth weight and gestational age of the infants were similar between the two groups; the SMA BFV measurements were performed at 9.4±1.7 and 8.6±1.5 days of life for the probiotic and placebo groups, respectively, P ¼ 0.07. The mean feeding volumes recorded during the SMA BFV were similar between the groups as well as mean daily enteral intake and the number of days required to reach full enteral feedings,
Intestinal blood flow in preterm infants T Havranek et al defined as 150 ml kg À1 day À1 (probiotic group 23.9 ± 8.3 days, placebo group 22.1 ± 8.5 days, P ¼ 0.55). Clinical variables known to affect SMA BFV, such as phototherapy, caffeine administration and patent ductus arteriosus status, did not differ between the two groups.
The main finding of our study is the statistically significant difference in the magnitude of postprandial TAMV increase (P ¼ 0.035) between the two groups, with PSV and EDV showing a trend 60 min postprandially (Figure 1 ). In consensus with other studies, 10, 12, 13 postprandial SMA BFVs at 30 and 60 min tended to increase from baseline the preprandial values for both the probiotic and placebo groups in response to administered feedings, although this increase was not statistically significant within each group and was more prominent in the probiotic group (Table 2) .
Discussion
To the best of our knowledge, our report is the first clinical trial evaluating the effects of probiotics on intestinal blood flow in human subjects. In the present study, probiotic-supplemented infants had higher postprandial SMA BFVs, with the TAMV increase from baseline being statistically significant 60 min after the feeding was initiated. The increase in PSV/EDV did not reach statistical significance, however, the values were higher in the probiotic vs the placebo group. Traditionally, greater increases in postprandial SMA BFV in preterm neonates are associated with less intestinal dysmotility 14 and with better tolerance to enteral feedings. 10 In our study, not sufficiently powered to detect differences in clinical outcome variables, we did not observe any difference in days to full ) from a preprandial state to 60 min after an enteral feeding for infants in the probiotic and control groups. *P<0.04; probiotic vs control.
feeds; in the placebo group, one infant had necrotizing enterocolitis and one had intestinal perforation.
Infants in our study groups were well matched in demographic and clinical variables known to affect SMA BFV measurements. However, neonates in the probiotic group had SMA BFV evaluated somewhat later (9.4 ± 1.7 vs 8.6 ± 1.5 days, P ¼ 0.07) and were more often exposed to caffeine (100% vs 81%, P ¼ 0.08). Although SMA BFV increases with chronological age, [15] [16] [17] [18] it tends to decrease after caffeine administration. [19] [20] [21] Interestingly, sepsis, a condition associated with splanchnic hyperemia in preterm neonates, 22 was documented twice as often in the placebo group than in the probiotic group (6 vs 3 cases, not significant). We speculate that the relatively small increase in pre-to postprandial SMA BFV is likely due to the participants having very low gestational and postnatal ages and the high incidence of patent ductus arteriosus in both groups; the effect of probiotics seems to enhance the postprandial response in the treatment group.
Explanation for such SMA BFV increase in the probiotic group could be potentially found in animal studies, 7, 8 which investigated the role of probiotic-generated trace amines (tyramine and b-phenylethylamine). In guinea-pig and rat models, mesenteric vasculature, rings of aorta and coronary arteries were isolated and exposed to the gradually increasing concentrations of tyramine and b-phenylethylamine, leading to vasoconstriction of the aorta and coronary arteries and relaxation of the mesenteric vascular bed. Furthermore, this response was independent of a sympathomimetic action, likely mediated via recently described trace amine-associated receptors. The authors concluded that 'after ingestion, trace amines could stimulate the gut and improve intestinal blood flow'. 7 Our study, designed as randomized, double-blinded clinical trial suggests a novel beneficial probiotic effect on the gut of premature infants, who are at the risk of feeding intolerance and necrotizing enterocolitis. Additional studies, perhaps involving different probiotic strains and feeding regimens will be needed to verify the finding of this clinical trial. 
